TipHub

457.55

+7.47 +1.66%

29 Jul 2026

NSE Listed · Pharmaceuticals

LT-ASM · ASM 4
What does LT-ASM · ASM 4 mean?
BSE · Long Term Additional Surveillance Measure (ASM 4)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-01
NSE · Long Term Additional Surveillance Measure (ASM 4)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

Bliss GVS Pharma Ltd. (BLISSGVS)

Volume: 35,913Avg Vol 1W: 1,87,465Avg Vol 1M: 4,00,34052W Range:118553
Key Ratios
Checked 2h ago
Market Cap₹4,841 Cr
Current Price₹457.55
Previous Close₹450.08
High / Low (52w)₹553 / ₹118
Volume35,913
Avg Vol (1W)1,87,465
Avg Vol (1M)4,00,340
Stock P/E141.77
Book Value₹112.75
Dividend Yield0.23%
ROE8.95%
ROA7.12%
Revenue (TTM)
Revenue Growth5.13%
Profit Margin11.15%
Total Debt₹20 Cr
Shares Outstanding11 Cr
Face Value₹1
EPS (TTM)₹3.22
P/B4.05
Debt / Equity0.09
50 DMA₹455.48
200 DMA₹261.4
Day change+1.66%
SurveillanceLT-ASM · ASM 4
Price Chart
457.55 194.21% · 1Y
5401285.8Cr
2025-07-29
2026-07-29

20-day avg volume: 3.3L shares

Pros
  • Company is almost debt-free.
  • Revenue grew 373% YoY.
  • Net profit is growing year over year.
Cons
  • Stock trades at a high P/E of 142.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹184 Cr₹218 Cr₹210 Cr₹198 Cr₹207 Cr₹244 Cr₹218 Cr₹257 Cr
EBITDA₹32 Cr₹40 Cr₹38 Cr₹25 Cr₹69 Cr₹44 Cr₹45 Cr₹47 Cr
Net Profit₹21 Cr₹24 Cr₹24 Cr₹16 Cr₹43 Cr₹27 Cr₹23 Cr₹36 Cr
EPS
Profit & Loss (Annual)
MetricDec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026
Revenue₹180 Cr₹846 Cr₹156 Cr₹163 Cr₹190 Cr₹165 Cr₹1,001 Cr₹212 Cr
EBITDA₹30 Cr₹134 Cr₹16 Cr₹36 Cr₹36 Cr₹29 Cr₹204 Cr₹46 Cr
Net Profit₹21 Cr₹84 Cr₹11 Cr₹21 Cr₹25 Cr₹19 Cr₹129 Cr₹32 Cr
EPS7.9512
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹905 Cr₹1,027 Cr₹1,077 Cr₹1,109 Cr₹1,157 Cr₹1,212 Cr₹1,301 Cr₹1,492 Cr
Total Liabilities₹245 Cr₹277 Cr₹249 Cr₹262 Cr₹239 Cr₹209 Cr₹209 Cr₹261 Cr
Equity₹660 Cr₹750 Cr₹828 Cr₹846 Cr₹917 Cr₹1,003 Cr₹1,092 Cr₹1,232 Cr
Total Debt
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹-12 Cr₹85 Cr₹93 Cr₹169 Cr₹79 Cr₹138 Cr₹145 Cr₹181 Cr
Investing₹-74 Cr₹-48 Cr₹-47 Cr₹-93 Cr₹-8 Cr₹-83 Cr₹-76 Cr₹-38 Cr
Financing₹17 Cr₹-6 Cr₹-21 Cr₹-24 Cr₹-25 Cr₹-21 Cr₹-30 Cr₹-89 Cr
Free Cash Flow₹-12 Cr₹85 Cr₹93 Cr₹169 Cr₹79 Cr₹138 Cr₹145 Cr₹181 Cr
Shareholding
Promoter 35.01% Institutions 17.54% Public 47.45%
Efficiency & Working Capital
ROCE9.2%
Interest Coverage16.8
Dividend Payout
Debtor Days204 d
Inventory Days59 d
Payable Days41 d
Cash Conversion Cycle222 d
Working Capital Days263 d
Shareholding Details

As of 2026-06-30

Promoter35%
FII8.1%
DII9.5%
Institutions17.5%
Public47.5%
Promoter Pledge0%
No. of Shareholders46,767
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters35.1%35%35%34.9%34.8%35.1%35.3%35.4%35.4%35.4%35.4%35%
FIIs16.3%15.3%14.7%13.2%12.1%13.5%13.2%12.7%13.3%14.5%10.4%8.1%
DIIs6.6%6.6%6.6%6.6%6.6%6.6%6.6%6.5%6%5.8%5%9.5%
Public42%43.1%43.7%45.3%46.5%44.8%45%45.4%45.4%44.3%49.2%47.5%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders43,23440,75845,15744,73752,93749,55849,51746,70744,46143,38044,87446,767
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603
Major Shareholders (>1%)
NameCategoryStakeShares
Narsimha Shibroor KamathShareholding of Promoter and Promoter Group30.6%3.24 Cr
Gulbarga Trading And Investment PrivatePublic Shareholding5.5%58,32,000
Arjun Gautam Ashra .Public Shareholding4.8%50,49,000
Clarus Capital IPublic Shareholding3.5%37,19,539
Life Insurance Corporation Of IndiaPublic Shareholding3.2%34,40,388
Gautam Rasiklal AshraPublic Shareholding2.8%29,81,571
Vibha Gagan SharmaShareholding of Promoter and Promoter Group2.4%25,75,000
Shruti Vishal RaoShareholding of Promoter and Promoter Group2%21,10,000
Coeus Global Opportunities FundPublic Shareholding1.8%18,59,594
Arian Investment LimitedPublic Shareholding1.4%14,43,888
360 One Pipe FundPublic Shareholding1.2%12,30,285
Mateus LtdPublic Shareholding1.1%11,50,000
Shibroor Gokuldas KamathShareholding of Promoter and Promoter Group0%8,000
Ramadas Vasudev Kamath.Shareholding of Promoter and Promoter Group0%100
Ramadas Vasudev Kamath HufShareholding of Promoter and Promoter Group0%0
Punita SharmaShareholding of Promoter and Promoter Group0%0
Gagan Harsh SharmaShareholding of Promoter and Promoter Group0%0
Geeta Narsimha KamathShareholding of Promoter and Promoter Group0%0
Shibroor Ravidas KamathShareholding of Promoter and Promoter Group0%0
Vishal Vijay RaoShareholding of Promoter and Promoter Group0%0
Shiv Kumar SharmaShareholding of Promoter and Promoter Group0%0
Radha SharmaShareholding of Promoter and Promoter Group0%0
Shagun SharmaShareholding of Promoter and Promoter Group0%0
Lalneet SharmaShareholding of Promoter and Promoter Group0%0
Vijay Bhawanishanker RaoShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Nandkumar Kashinath ChodankarChairman & Independent Directo2026
Shilpa BhatiaIndependent Non Executive Women Director2026
Shibroor N KamathED / MD / CEO / Promoter2026
Vijayanarayanan MahadevanIndependent Non Exe. Director2026
Deepak Rameshchandra ShahIndependent Non Exe. Director2026
Aditi BhattCompany Secretary2026
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr
Segments — Geography
RegionRevenueShare
Outside India₹616 Cr93.1%
Within India₹46 Cr6.9%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹1151111
Corporate Actions
TypeDateValueRemark
forthcoming2026-07-08Dividend (1/- per share)Final
dividend2026-07-08₹1 (100%)Final
dividend2026-02-18₹0.5 (50%)Interim
dividend2025-07-24₹0.5 (50%)Final
forthcomingBook ClosureAGM
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20261900097208
20261110023117
20262007514
Insider / Designated-Person Trades

7 recent disclosure(s)

Mrs. Punita SharmaDisposal · 24,962
Mr. Gagan Harsh SharmaDisposal · 2,17,123
Mr. Gagan Harsh SharmaDisposal · 2,17,123
Mrs. Punita SharmaDisposal · 24,962
Mr. Gagan Harsh SharmaAcquisition · 2,123
Mr. Gagan Harsh SharmaAcquisition · 10,000
Substantial Acquisitions (SAST)

1 disclosure(s)

Market18/05/2026 · 24,962
Company Information
Incorporated1984
ChairmanNandkumar Kashinath Chodankar
AuditorKalyaniwalla & Mistry LLP
🌐 www.blissgvs.com

📍 102 Hyde Park Sakivihar Road, Andheri East, Mumbai, Maharashtra, 400072

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search